Real-time polymerase chain reaction

QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems

Retrieved on: 
Monday, January 8, 2024
Dicarboxylic acid, Food, FDA, QGEN, QIAGEN, Real-time polymerase chain reaction, Infection, DNA, PCR, Genetically modified bacteria, STI, Chlamydia trachomatis, Neisseria gonorrhoeae, Diagnosis, Senior

The majority of these infections are asymptomatic and generally curable with existing single-dose regimens of antibiotics.

Key Points: 
  • The majority of these infections are asymptomatic and generally curable with existing single-dose regimens of antibiotics.
  • This FDA clearance supports the test menu expansion for NeuMoDx Molecular Systems in the U.S.
  • The systems extract DNA to isolate the target nucleic acids and then conduct a real-time polymerase chain reaction (RT-PCR).
  • For more information about the NeuMoDx assay menu, please visit https://go.qiagen.com/neumodx

Diatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in Oncology

Retrieved on: 
Tuesday, June 20, 2023
Oncology, Health, Biometrics, Other Health, General Health, Pharmaceutical, Real-time polymerase chain reaction, Neoplasm, Bone marrow, Pharmacogenomics, Cancer, Bladder cancer, Janssen, Patient, Medicine, IVD, Growth, PCR, Medical imaging, EU, WHO model list of essential in vitro diagnostics

Diatech Pharmacogenetics (“Diatech”) has established a collaboration agreement with Janssen Pharmaceutica NV with the aim of improving access to precision medicine for patients with bladder cancer.

Key Points: 
  • Diatech Pharmacogenetics (“Diatech”) has established a collaboration agreement with Janssen Pharmaceutica NV with the aim of improving access to precision medicine for patients with bladder cancer.
  • As one of Europe's leading precision medicine companies, Diatech Pharmacogenetics researches and manufactures In Vitro Diagnostic (IVD) tests in oncology for various types of solid tumours and blood cancers.
  • Diatech Pharmacogenetics is working on the development of a new molecular test dedicated to bladder cancer, with the aim to enable patients access precision drug treatments, based on their individual molecular profile.
  • Diatech Pharmacogenetics is a leading Italian company in the development, production and commercialization of molecular diagnostic tools for precision oncology medicine.

Clinical Microbiology Global Market Report 2022: Industry to Reach $5.7 Billion by 2027 at a 6.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 27, 2022
Health, Biotechnology, Water pollution, Automation, NGS, Traction, Real-time polymerase chain reaction, Infection, Atmosphere, Machine learning, Degenerative disease, Mass spectrometry, Prevalence, PCR, Vaccine, Medical device, Growth

The "Clinical Microbiology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Microbiology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global clinical microbiology market size reached US$ 3.9 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 5.7 Billion by 2027, exhibiting a CAGR of 6.53% during 2021-2027.
  • Clinical microbiology is a field of medical science that assists in diagnosing, preventing, and treating various infectious diseases.

Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels

Retrieved on: 
Tuesday, December 6, 2022
Technology, Manufacturing, Other Technology, Other Science, Other Manufacturing, Research, Science, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Infection, PPD, Mindful Scientific Inc., Workflow, Research, Science, TaqMan, Patheon, PCR, West Pharmaceutical Services explosion, Real-time, Real-time polymerase chain reaction, Applied Biosystems, Vertically transmitted infection, Genetic, MagMax, Genetic testing, Health, Vaccine

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.
  • TrueMark Infectious Disease Research Panels are analytically sensitive, real-time polymerase chain reaction (PCR) syndromic panels for the analysis of a wide range of infectious disease pathogens.
  • With the TrueMark Infectious Disease Research Panels, laboratories can choose either the readymade panels or create their own custom panels to suit their needs, said Dr. Manoj Gandhi, senior medical director of Genetic Testing Solutions at Thermo Fisher Scientific.
  • For more information on the TrueMark Infectious Disease Research Panels, please visit www.thermofisher.com/truemarkpluspanels .

United States Molecular Diagnostics Market Analysis Report 2022: A $12.5 Billion Market by 2027 - Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Health, Biotechnology, COVID-19, Diagnosis, BioMérieux, Laboratory, Infection, Cell, Gene, United States national laboratories, Abbott Laboratories, Myriad Genetics, Roche Diagnostics, Projection, Patient, POC, Proteome, Government, Gen-Probe, NHS England, Ageing, Cancer, Genome, Protein, FISH, RNA transfection, PCR, Abbott, Power-on self-test, ID, Prognosis, Genetic testing, Death, CE, ISH, Research, Real-time polymerase chain reaction, Danaher Corporation, Cobas, Coronavirus, NHS, England, Investment, Pharmaceutical industry, Medical device, Medical imaging, Growth

The "United States Molecular Diagnostics Market, Size, Share, Forecast 2022-2027, Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Molecular Diagnostics Market, Size, Share, Forecast 2022-2027, Industry Trends, Growth, Insights, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Molecular diagnostics has developed as a superior methodology in the United States over the previous decade, achieving the goal of speedier disease diagnosis with fewer complexities.
  • The COVID-19 outbreak is expected to boost the growth of the Molecular Diagnostics Market in the United States.
  • In the United States molecular diagnostics market in 2021, the infectious illness category held the most significant market share.

QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Telemedicine, Virtual Medicine, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Hospitals, Other Health, Blood, Molecular diagnostics, Automation, Senior, World Health Organization, WHO, Knowledge, QGEN, Infection, PCR, Patient, DNA, MOVEit, NYSE, Organic acid, Stanford University v. Roche Molecular Systems, Inc., Life, Real-time polymerase chain reaction, Research, Monkeypox, IVD, Protein, Growth, RNA, QIAGEN, RUO, Pharmaceutical industry, Vaccine, Pharma, Insight

The NeuMoDx MPXV Test Strip currently for research use only (RUO) is a multiplex test that identifies both clades (variants) of monkeypox.

Key Points: 
  • The NeuMoDx MPXV Test Strip currently for research use only (RUO) is a multiplex test that identifies both clades (variants) of monkeypox.
  • The NeuMoDx assay extracts DNA from lesion fluid swabs to isolate the target nucleic acids and then conducts a real-time polymerase chain reaction.
  • QIAGEN has been working with healthcare authorities around the world since the global monkeypox outbreak began this spring to contribute its broad testing portfolio and expertise as a trusted partner in an urgent global health response.
  • QIAGEN this summer launched the QIAstat-Dx Viral Vesicular Panel RUO, the worlds first syndromic test, for research use only, to differentiate between monkeypox and five other pathogens that cause similar symptoms.

QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System

Retrieved on: 
Thursday, September 15, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Chlamydia trachomatis, Molecular diagnostics, QIAGEN, Real-time polymerase chain reaction, Knowledge, COVID-19, NYSE, Risk, Organic acid, Blood, QGEN, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, Life, Growth, Monkeypox, EU, Patient, RSV, Certification, Viral load, Reproductive health, Stanford University v. Roche Molecular Systems, Inc., Protein, Immunodeficiency, Solution, HPV, RNA, Research, DNA, Urine, Automation, EBV, SEC, Union, Mortality, Budget, Organ transplantation, Vaccine, Insight, Academy, Chlamydia, Pharma

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.
  • The new assays support QIAGENs strategy of expanding the menu of tests available for use on the NeuMoDx 96 and 288 Molecular Systems.
  • The assay adds to the broad portfolio that QIAGEN offers to address all testing needs around monkeypox.
  • QIAGEN remains committed to responding to the COVID-19 endemic by preparing to launch a new multiple-target test: NeuMoDx FluA/FluB/RSV/SARS-CoV-2 Assay with a new dual-target SARS-CoV-2 design.

Immunoassay Technology Developer Spear Bio Presents Its NAB-SureTM SARS-CoV2 Neutralizing Antibody Test Kit at the American Association of Clinical Chemistry's Annual Event

Retrieved on: 
Friday, September 2, 2022
COVID-19, Wyss Institute for Biologically Inspired Engineering, Technology, DBS, American Association for Clinical Chemistry, View, AACC, Serum, Wyss Institute, SPEAR, ELISA, Multimedia, Harvard University, NAB, Severe acute respiratory syndrome coronavirus 2, PCR, Plasma, Real-time polymerase chain reaction, Association, Signal-to-noise ratio, CTO, Industry, Neutralizing antibody, Government, PRNT, American Association, Vaccine, Pharmaceutical industry, Metabolomics

WOBURN, Mass., Sept. 2, 2022 /PRNewswire/ -- Developer of an ultrasensitive protein detection platform, Spear Bio (www.spear.bio), presented its breakthrough immunoassay technology at the recent American Association of Clinical Chemistry's scientific meeting and clinical lab expo, held in Chicago.  

Key Points: 
  • At the AACC event Spear Bio unveiled its first product to market: the NAB-Sure SARS-CoV-2 neutralizing antibody (NAb) test kit.
  • Based on proprietary SPEAR technology, the NAB-Sure SARS-CoV-2 Assay is a powerful research tool in the fight against COVID-19 coronavirus disease.
  • It serves a variety of applications, including COVID-19 serosurveillance, vaccine efficacy testing, and longitudinal antibody durability testing.
  • The immunoassay test kit is capable of ultrasensitive protein detection for small sample sizes, such as dried blood spot (DBS) samples from a finger prick, which can be collected in-home.

DGAP-News: Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference

Retrieved on: 
Thursday, September 1, 2022
DGAP, Neoplasm, Security (finance), COVID-19, Cancer, Ageing, United Arab Emirates, NASDAQ, News, Death, Colon, American Cancer Society, Real-time polymerase chain reaction, Colorectal cancer, DNA, Union, SEC, U.S. Securities and Exchange Commission, Large intestine, PCR, FIT, Intention, Conference, FDA, Company, Form, Emirates, Biomarker, Lotte New York Palace Hotel, CRC, SEC filing, Private Securities Litigation Reform Act, Health, Forward-looking statement, Trial of the century, Patient, Video game, Pharmaceutical industry, Vaccine, EU

Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference

Key Points: 
  • Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference
    The issuer is solely responsible for the content of this announcement.
  • BERKELEY, US MAINZ, Germany SEPTEMBER 01, 2022 Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will present at the H.C. Wainwright Annual Global Investment Conference taking place from September 12-14, 2022.
  • The in-person conference is being held at the Lotte New York Palace Hotel in New York City.
  • To access Mainzs presentation at the Annual Global Investment Conference, please visit https://hcwevents.com/annualconference/ to register for the event.

Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference

Retrieved on: 
Thursday, September 1, 2022
Neoplasm, Security (finance), COVID-19, Cancer, Ageing, United Arab Emirates, NASDAQ, Death, Colon, American Cancer Society, Real-time polymerase chain reaction, Colorectal cancer, DNA, Union, SEC, U.S. Securities and Exchange Commission, Large intestine, PCR, GLOBE, Intention, FIT, Conference, FDA, Company, Form, Emirates, Biomarker, Lotte New York Palace Hotel, CRC, SEC filing, Private Securities Litigation Reform Act, Health, Forward-looking statement, Trial of the century, Patient, Pharmaceutical industry, Vaccine, EU

BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will present at the H.C. Wainwright Annual Global Investment Conference taking place from September 12-14, 2022.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will present at the H.C. Wainwright Annual Global Investment Conference taking place from September 12-14, 2022.
  • The in-person conference is being held at the Lotte New York Palace Hotel in New York City.
  • To access Mainzs presentation at the Annual Global Investment Conference, please visit https://hcwevents.com/annualconference/ to register for the event.
  • The product is commercially available in a selection of countries in the European Union and in the United Arab Emirates.